共 44 条
[1]
Kearon C(2012)Antithrombotic therapy for VTE disease, antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians, Evidence-Based Clinical Practice Guidelines Chest 141 e419S-e494S
[2]
Akl EA(1999)Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) Lancet 353 1386-1389
[3]
Comerota AJ(2014)Fibrinolysis for patients with intermediate-risk pulmonary embolism N Engl J Med 370 1402-1411
[4]
Goldhaber SZ(2014)Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: a systematic review and meta-analysis Thromb Res 133 357-363
[5]
Visani L(2010)Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial Chest 137 254-262
[6]
DeRosa M(2014)Half-dose recombinant tissue plasminogen activator treatment in venous thromboembolism J Investig Med 62 71-77
[7]
Meyer G(2013)Moderate pulmonary embolism treated with thrombolysis Am J Cardiol 111 273-277
[8]
Vicaut E(2014)Safe dose thrombolysis plus rivaroxaban in the treatment of moderate and severe pulmonary embolism: drip, drug, and discharge Clin Cardiol 37 780-782
[9]
Danays T(2011)Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association Circulation 123 1788-1830
[10]
Zhang Z(2014)Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism Circulation 129 479-486